Amgen scraps or halts a slate of 5 cancer studies in a series of setbacks. But execs focus on mastering 'induced proximity'
Amgen rolled out their Q4 numbers Tuesday afternoon, while flagging that a long lineup of its cancer therapy studies has been halted as they review …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
